Related Experiment Videos
Elevation of bilirubin production in neonatal rats treated with nicardipine hydrochloride
Developmental Pharmacology and Therapeutics
|January 1, 1987
Insights
Maternal administration of nicardipine hydrochloride, a calcium channel blocker, increased bilirubin production by 30% in neonatal rats. This suggests potential effects on infant bilirubin levels during pregnancy.
Area of Science:
- Neonatal pharmacology
- Bilirubin metabolism
- Calcium channel blockers
Background:
- Nicardipine hydrochloride is a dihydropyridine calcium entry blocker used in tocolysis.
- Elevated bilirubin levels in neonates can lead to serious health issues like jaundice.
- The impact of maternal nicardipine administration on neonatal bilirubin metabolism is not fully understood.
Purpose of the Study:
- To investigate the effect of maternal nicardipine hydrochloride administration on bilirubin formation and plasma concentrations in neonatal rats.
Main Methods:
- Neonatal rats were administered nicardipine hydrochloride.
- Bilirubin formation rates and plasma bilirubin concentrations were measured.
Main Results:
- A 30% increase in the rate of bilirubin formation was observed in neonatal rats exposed to nicardipine hydrochloride.
- Plasma bilirubin concentrations significantly increased from 0.83 +/- 0.05 to 1.06 +/- 0.10 mg/100 ml (p < 0.05).
Conclusions:
- Maternal administration of nicardipine hydrochloride may enhance bilirubin production in neonates.
- These findings suggest a potential mechanism by which tocolytic use of nicardipine hydrochloride could influence neonatal hyperbilirubinemia.
Abstract:
Administration of nicardipine hydrochloride, a dihydropyridine calcium entry blocker, caused a 30% rise in the rate of bilirubin formation in neonatal rats. Plasma bilirubin concentrations also increased from 0.83 +/- 0.05 to 1.06 +/- 0.10 mg/100 ml (p less than 0.05). We conclude that maternal administration of nicardipine hydrochloride for tocolysis could affect bilirubin production in the neonate.